RISK FOR HERPES ZOSTER AFTER TREATMENT WITH BIOLOGIC AND SYNTHETIC DISEASE MODIFYING AGENTS FOR RHEUMATOID ARTHRITIS

被引：0
|
作者：
Pappas, D. A. [1 ]
Hooper, M. [2 ]
Reed, G. [3 ]
Shan, Y. [3 ]
Wenkert, D. [2 ]
Zhang, J. [4 ]
Greenberg, J. [5 ]
Curtis, J.
机构：
[1] Columbia Univ, New York, NY USA
[2] Amgen Inc, Thousand Oaks, CA USA
[3] Univ Massachusetts, Med Ctr, Worcester, MA USA
[4] Univ Alabama Birmingham, Birmingham, AL USA
[5] NYU, Langone Med Sch, New York, NY USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2013年 / 71卷
关键词：
D O I：
10.1136/annrheumdis-2012-eular.2565
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：346 / 346
页数：1
相关论文
共 50 条
  • [21] Facility-Level Variation in Biologic Disease Modifying Agents for Medicare Enrollees with Rheumatoid Arthritis
    Dalal, Deepan
    Zhang, Tingting
    Verma, Hiren
    Shireman, Theresa
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [22] Rates and risk factors for Herpes Zoster in patients with rheumatoid arthritis
    Wolfe, F
    Michaud, K
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 103 - 104
  • [23] Herpes zoster risk in DMARD-treated rheumatoid arthritis
    Thorley, Jennifer
    LANCET RHEUMATOLOGY, 2021, 3 (09): : E618 - E618
  • [24] TREATMENT ADHERENCE TO CONVENTIONAL AND BIOLOGIC DISEASE MODIFYING ANTIRHEUMATIC DRUGS IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Feldman, C. H.
    Lii, J.
    Gopalakrishnan, C.
    Franklin, J. M.
    Kim, S. C.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 526 - 526
  • [25] ANNUAL TREATMENT COST OF BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS
    Hosseini, R.
    Brown, L. M.
    Fleming, M.
    Rodriguez-Monguio, R.
    Seoane-Vazquez, E.
    VALUE IN HEALTH, 2024, 27 (06) : S110 - S110
  • [26] Cardiovascular Risk and the Use of Biologic Agents in Rheumatoid Arthritis
    Lim, Debbie T.
    Cannella, Amy C.
    Michaud, Kaleb D.
    Mikuls, Ted R.
    CURRENT RHEUMATOLOGY REPORTS, 2014, 16 (11)
  • [27] Cardiovascular Risk and the Use of Biologic Agents in Rheumatoid Arthritis
    Debbie T. Lim
    Amy C. Cannella
    Kaleb D Michaud
    Ted R. Mikuls
    Current Rheumatology Reports, 2014, 16
  • [28] Treatment in rheumatoid arthritis and mortality risk in clinical practice: the role of biologic agents
    Rodriguez-Rodriguez, L.
    Leon, L.
    Ivorra-Cortes, J.
    Gomez, A.
    Lamas, J. R.
    Pato, E.
    Jover, J. A.
    Abasolol, L.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (06) : 1026 - 1032
  • [29] Risk of herpes zoster in psoriatic patients undergoing biologic treatment
    Umezawa, Yoshinori
    Fukuchi, Osamu
    Ito, Toshihiro
    Saeki, Hidehisa
    Nakagawa, Hidemi
    JOURNAL OF DERMATOLOGY, 2014, 41 (02): : 168 - 170
  • [30] Lipids and lipid changes with synthetic and biologic disease-modifying antirheumatic drug therapy in rheumatoid arthritis: implications for cardiovascular risk
    Myasoedova, Elena
    CURRENT OPINION IN RHEUMATOLOGY, 2017, 29 (03) : 277 - 284
12345